2020-11-12| R&DTrials & Approvals

Pfizer’s JAK1 Inhibitor Impresses in Phase 3 Atopic Dermatitis Trial

by Daniel Ojeda
Share To

On November 11th, Pfizer announced the results for their Phase 3 JADE REGIMEN study, which aimed to determine the efficacy of Abrocitinib in patients with moderate to acute atopic dermatitis (AD). Treatment with Abrocitinib resulted in an Investigator’s Global Assessment (IGA) response of clear or almost clear, defined as no inflammatory signs or just perceptible erythema, for over 60% percent of treated patients. Crucially, most of these patients continued to respond to the treatment for the full duration of the trial, so they did not develop resistance to the treatment.

Atopic dermatitis is a chronic inflammatory disease characterized by red scaly patches of skin and severe itching. In the USA, around 9.6 million children and 16.5 million adults suffer from AD. Worldwide, AD affects up to 10% of adults and 20% of children, with the rate in the case increasing since the late 1990s.

There is no available cure for AD; however, oral or topical corticosteroids can reduce the inflammation and control itchiness in some patients. Other medications include calcineurin inhibitors, and the newly FDA approved IL-4 receptor antagonist Dupilumab. Not all patients respond to these medications, and Dupilumab must be injected. For this reason, new orally available effective therapeutic options are necessary.



The JADE REGIMEN was a randomized, responder-enriched, double-blind, placebo-controlled, Phase 3 withdrawal trial. The trials took place over 52 weeks. First, all patients received 200mg of Abrocitinib for 12 weeks to determine the responder status. Of the 1233 patients, 64.6% responded to Abrocitinib, which was a higher percentage than expected. These patients were assigned to one of three groups, 100mg, 200mg Abrocitinib, or placebo for a 40-week, double-blind, maintenance period. The results showed that patients in the two Abrocitinib groups were less likely to experience a flare, with 81.1% and 57.4% of patients not experiencing a flare, versus 19.1 % in placebo. Furthermore, no new safety signals were observed during the study.

“Atopic dermatitis brings a lot of uncertainty and disruption to daily life, and the unpredictability of flares can make treating and managing the disease complex and frustrating,” said Michael Corbo, Ph.D., Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “These latest results from our Phase 3 clinical trial program shed light on the potential Abrocitinib, if approved, could have to prevent troublesome flares in patients.”


JAK Inhibitors Against AD

Abrocitinib is an orally available small molecule that inhibits the Janus Kinase (JAK) 1 protein. Inhibition of this protein modulates the levels of multiple inflammatory molecules thought to be involved in the pathology of AD. Pfizer has received Priority Review designation by the U.S. Food and Drug Administration and Marketing Authorization Application by the European Medicines Agency for Abrocitinib. However, this is not the only JAK inhibitor currently being tested for the treatment of AD.

Currently, there are other JAK inhibitors in Phase 3 clinical trials. A few examples are Upadacitinib, developed by AbbVie, and Baricitinib, co-developed by Olumiant and Elli Lilly. Furthermore, Incyte, in collaboration with Pfizer, is testing a second JAK inhibitor, Ruxolitinib, for the treatment of AD. Not far behind is the pan-JAK inhibitor Delgocitinib, currently in Phase 2a clinical trials, which was developed by drug manufacturer Torri and Japan tobacco.

By Daniel Ojeda, Ph.D.

Related Article: Pfizer Announces Positive Top-Line Results for JAK Inhibitor in Ankylosing Spondylitis Trial



© All rights reserved. Collaborate with us: [email protected]
Related Post
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
Scroll to Top